Clinical Diagnosis

The first in a series of upgrades to Stellaris Elite incudes maximum vacuum increase and trocar/cannula system removeable valve cap enhancement.

According to investigators, patients with age-related macular degeneration like the port delivery system for ranibizumab because it requires fewer treatments and there is less discomfort.

Kala Pharmaceuticals Inc. announced that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was first announced in May.

According to William B. Trattler, MD, progression of the disease before cross-linking often can be identified over a period of months.

According to Mark Lobanoff, DO, earlier treatment also can mean the best possible results for patients.

Lloyd Clark, MD, highlights his ASRS presentation focusing on the PANORAMA study detailing the use of aflibercept in the management of diabetic retinopathy.

David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.

Rahul Khurana, MD, shares a preview of his ASRS poster based on an analysis of the second year of the VIEW 1 and VIEW 2 studies comparing aflibercept and ranibizumab treatment arms.

Investigators have found that recordings from the retina could identify distinct signals for both attention deficit hyperactivity disorder and autism spectrum disorder, providing a potential biomarker for each condition.

RegeneRx Biopharmaceuticals Inc. said its U.S. joint venture partner and licensee, HLB Therapeutics, will expand its ophthalmic clinical development program with RGN-259 in two indications, neurotrophic keratopathy and dry eye disease.

LumiThera Inc. noted that the trial results demonstrated statistically significant improvement in the prespecified primary endpoint in BCVA at 13 months in the PBM treatment group over the sham-treatment group.

As ophthalmologists observe Cataract Awareness Month this June, William L. Soscia, MD, medical director at Center for Sight, in Sarasota, Florida, focuses on the importance of having excellent vision for safety and everyday functions.

The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only therapy available in the United States for suprachoroidal use in the treatment of macular edema associated with uveitis.

A team led by researchers from the University of Geneva has identified a molecular mechanism that causes degeneration of the eye’s photoreceptors, which can lead to blindness.

Jason Menzo is named CEO, while Russell Kelley, PhD, MBA, will become managing director of the RD Fund. Ben Yerxa, PhD, will take the helm of Opus Genetics, the first RD Fund- and foundation-backed spin-off company.

Researchers believe this may be the first report of the use of topical brimonidine gel for the treatment of eyelid ptosis associated with cosmetic use of botulinum toxin.

A study by Orbis International found that children with myopia experienced significantly higher levels of depression and anxiety than their peers without vision impairment.

Foundation Fighting Blindness is among a group of investors offering financial support for Nacuity’s efforts to stop oxidative tissue damage, a driver of blinding eye diseases.

According to the organization, the eBook content is designed for residents, ophthalmologists, fellows, medical students and other professionals performing or supporting cataract surgery.

As dexamethasone adds indications, a study confirms efficacy of punctal occlusion for allergic conjunctivitis.

The treatments typically include application of heat, lid hygiene, and massage of eyelid.

Having a comprehensive team of ophthalmic specialists in place means patients could have multiple issues treated in a single procedure that might require two surgeries otherwise.

The study investigates 3-year intravitreal implant in eyes with active noninfectious posterior uveitis.

The research from eye care nonprofit Orbis International focuses on diabetic retinopathy in Rwanda, where associated vision complications from diabetes are growing.

The systems could be in the hands of surgeons in the third quarter through a targeted initial launch, according to the company.

Study demonstrates results of pegcetacoplan as a geographic atrophy therapy.

The rare disorder is often a delayed or misdiagnosed condition, resulting in unnecessary referrals and imaging.